

BQ



Office de la Propriété
Intellectuelle
du Canada
Un organisme
d'Industrie Canada

Canadian
Intellectual Property
Office
An agency of
Industry Canada

CA 2251430, C 2005/1179

(11)(21) 2 251 430

(12) BREVET CANADIEN
CANADIAN PATENT
(22) C

(22) Date de dépôt /ing Date: 1998/10/21

(41) Mise à la disp. pub. /Open to Public Insp.: 2000/07/28

(42) Date de délivrance/issue Date: 2015/11/25

(63) Priorité/Priority: 1998/08/28 (09/14/1, 18/1) US

(51) Cl. Int. /Int. Cl.: A61K 31/4435, A61K 9/36, A61K 9/30, A61P 1/04

(72) Inventeurs/Inventors:
CHI N, CHIH MING, US;
CHOU, JOSEPH, US;
KOSHIPRAVA, UNCHAITI, US

(73) Propriétaire/Owner:
ANNEX PHARMACEUTICALS, INC., US

(74) Agent: MOFFAT & CO.

(51) Titre: PRÉPARATION D'OMEPRAZOLE
(54) Titre: OMEPRAZOLE FORMULATION

(57) Abrégé/Abstract

A pharmaceutical composition of omeprazole for oral administration is described which consists essentially of: (a) a tableted core component containing a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent.

Canada

<http://ipic.gc.ca> • Ottawa-Hull K1A 0G9 • info@ipic.gc.ca

CIPC • CIPO 101

OPIC



CIPO

BEST AVAILABLE COPY

CA 02251430 1998-10-21

ABSTRACT

A pharmaceutical composition of omeprazole for oral
5 administration is described which consists essentially
of:

- (a) a tableted core component containing a
therapeutically effective amount of omeprazole, a
surface active agent, a filler, a pharmaceutically
10 acceptable alkaline agent and a binder; and
- (b) a single layer of coating on said core which
comprises a layer of an enteric coating agent.

CA 02251430 2003-12-01

OMEPRAZOLE FORMULATION

BACKGROUND OF THE INVENTION:

The present invention relates to a stable
5 formulation of omeprazole. It is well known that
omeprazole is sensitive to acidic conditions and after
contact with an acid, omeprazole will degrade and will
not function in its intended manner. Initially,
alkaline materials were added to a core of omeprazole
10 and later an enteric coating was applied over the core
to prevent the omeprazole from contacting the acidic pH
conditions of the stomach. This approach is
satisfactory if the product is administered within a
short time after it is manufactured but if the product
15 is stored under ambient conditions, the acidic residue
of the enteric coating appears to degrade the
omeprazole before it is administered to a patient. To
solve this problem, the prior art has used a separate
layer of a coating agent to coat a pellet core which
20 contains omeprazole and an alkaline material which is
thereafter coated with the enteric coating. This
technique is described in U.S. 4,786,505.

This dual layer coating technique requires the
application of two separate functional coating
25 operations which increases the length of the
manufacturing process and the cost of the product. The
applicant's have surprisingly discovered a coating
system which avoids the need to use a coating layer to
separate the omeprazole core from the enteric coating
30 layer in an omeprazole dosage form. The separate
coating system is based on the combined use of an
enteric coating agent which is applied to cores of
omeprazole as a suspension in an suitable solvent.

CA 02251430 2003-12-01

SUMMARY OF THE INVENTION

The present invention provides a novel dosage form of omeprazole which consists essentially of:

- 5 (a) a compressed tablet core made from a granulation comprising a therapeutically effective amount of omeprazole, a surface active agent, a filler, a pharmaceutically acceptable alkaline agent and a binder; and
- 10 (b) a single layer of coating on said core which comprises a layer of an enteric coating agent.

Accordingly, it is a primary object of this invention to provide a pharmaceutical dosage formulation of omeprazole which is stable upon prolonged storage, is

15 stable when administered to a patient and is capable of providing the desired therapeutic effect.

It is also an object of this invention to provide a pharmaceutical dosage form of omeprazole which is bioequivalent to dosage forms of omeprazole which have an

20 intermediate layer of an inert coating material.

It is also an object of this invention to provide a stable dosage form of omeprazole which may be produced without the need to provide an intermediate coating layer that separates the omeprazole containing core from the

25 enteric coating layer.

In a broad aspect, then, the present invention relates to a stable pharmaceutical dosage formulation for oral administration consisting essentially of: (a) a tablet core consisting essentially of 5 to 70 weight percent based

30 on the total weight of the core of omeprazole, 0.1 to 5 weight percent based on the total weight of the core of a surface active agent, 25 to 50 weight percent based on the total weight of the core of a filler, 0.1 to 10 weight percent based on the total weight of the core of a binder

35 and 20 to 60 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine; and (b) a coating layer

CA 02251430 2003-12-01

surrounding the core that consists of an enteric coating agent, 10 to 50 weight percent based on the total weight of the coating layer of an inert processing aid and 0 to 40 weight percent based on the total weight of the coating layer of a plasticizer wherein the coating layer is applied directly to the omeprazole containing core without a separating layer between the omeprazole containing core and coating layer.

In another broad aspect, then, the present invention relates to a method for preparing a stable oral pharmaceutical dosage formulation which consists essentially of: (a) forming a tablet core consisting essentially of 5 to 70 weight percent based on the total weight of the core of omeprazole, 0.1 to 10 weight percent based on the total weight of the core of a binder, 25 to 50 weight percent based on the total weight of the core of a filler, 0.1 to 5 weight percent based on the total weight percent of the core of a surface active agent and 20-60 weight percent based on the total weight of the core of an alkaline agent wherein the alkaline agent is selected from the group consisting of lysine and arginine; and (b) applying a coating layer to the tablet core that surrounds the tablet core and consists of an enteric coating agent, 10 to 50 weight percent based on the total weight of the coating layer of an inert processing aid and 0 to 40 weight percent based on the total weight of the coating layer of a plasticizer wherein the coating layer is applied directly to the omeprazole containing tablet core without a separating layer between the omeprazole containing tablet core and coating layer.

The objects and essence of the invention will become apparent from a review of the appended specification.

DETAILED DESCRIPTION OF THE INVENTION

The omeprazole formulation of the invention is preferably based on a compressed tablet core formed from a granulation which comprises omeprazole, a surface active agent, a filler, an alkaline material and a binder.

2a

CA 02251430 1998-10-11

The cimetidine may comprise from 5 to 70wt% and preferably 10 to 30wt% of the granulation.

The surface active agent may be any pharmaceutically acceptable, non-toxic surfactant. Suitable surface active agents include sodium lauryl sulfate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 and the like.

The surface active agent may be present at a level of from 0.1 to 5wt% and preferably 0.20 to 2.0wt% based on the total weight of the granulation.

The alkaline material is selected from the group consisting of the sodium, potassium, calcium, magnesium and aluminum salts of phosphoric acid, carbonic acid, citric acid and aluminum/magnesium compounds such as $Al_2O_3 \cdot 6H_2O \cdot CO_2 \cdot 12H_2O$, $(Mg, Al)_2(OH)_2CO_3 \cdot 4H_2O$, $MgO \cdot Al_2O_3 \cdot 2SiO_2 \cdot nH_2O$ where n is a whole integer of 2 or more. In addition the alkaline material may be selected from lysine or arginine or from the group consisting of antacid materials such as aluminum hydroxides, calcium hydroxides, magnesium hydroxides and magnesium oxide. The alkaline agent may be present at a level of 10 to 80wt% based on the total weight of the granulation, depending on the relative strength of the alkaline material. If the preferred arginine is employed, a level of from 20 to 60wt% and preferably 30 to 55wt% based on the weight of the granulation may be employed.

The binder may be any pharmaceutically acceptable, non-toxic pharmaceutically acceptable binder. The binder is preferably a water soluble polymer of the group consisting of polyvinyl alcohol, polyvinylpyrrolidone, methylcellulose, hydroxypropyl cellulose, hydroxymethyl cellulose and the like. A water soluble binder is preferred which is applied from an aqueous medium such as water at a level of from 0.1 to 10wt% and preferably from 0.25 to 7.5wt% of binder based on the total weight of the granulation.

CA 02251430 2003-12-01

A filler is used as a granulation substrate. Sugars such as lactose, dextrose, sucrose, maltose, or microcrystalline cellulose and the like may be used as fillers in the granulation composition. The filler may
5 comprise from 25 to 50wt% and preferably 20 to 40wt% based on the total weight of the granulation.

A tablet disintegrant may be added which comprises corn starch, potato starch, croscarmellose sodium, crospovidone and sodium starch glycolate in an effective
10 amount. An effective amount which may be from 3 to 7wt% based on the total weight of the granulation.

The enteric coating agent may comprise an acid resisting material which resists acid up to a pH of above about 5.0 or higher which is selected from the
15 group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylethylcellulose, Eudragit[®] L (poly(methacrylic acid, methylmethacrylate), 1:1 ratio; MW (No. Av. 135,000 - USP Type A) or Eudragit[®] S
20 (poly(methacrylic acid, methylmethacrylate, 1:2 ratio MW (No. Av. 135,000 - USP Type B) and mixtures thereof.

For example Eudragit[®] L100-55 is a 100% polymer solids product while the Eudragit[®] L30-55 product is a 30%w/w aqueous dispersion of the polymer. The enteric coating
25 agent may also include an inert processing aid in an amount from 10 to 50wt% and preferably 20 to 40wt% based on the total weight of the acid resisting component and the inert processing aid. The inert processing aid include finely divided forms of talc, silicon dioxide, magnesium stearate etc. Typical solvents which may be
30 used to apply the acid resisting component-inert processing aid mixture include isopropyl alcohol, acetone, methylene chloride and the like. Generally the acid resistant component-inert processing aid mixture
35 will be applied from a 5 to 20wt% of acid resisting component-inert processing aid mixture based on the

CA 02251430 2003-12-01

total weight of the solvent and the acid resistant component-inert processing aid.

The enteric coating may optionally comprise a plasticizer. Suitable plasticizers include acetyl triethyl citrate, dibutyl phthalate, tributyl citrate, triethyl citrate, acetyl tributyl citrate, propylene glycol, triacetin, polyethylene glycol and diethyl phthalate. The amount of plasticizer can vary, but will typically be present in the amount of 0 to 40% w/w based upon the weight acid resisting component of the coating, and more preferably about 10-20% w/w based upon the weight of the acid resisting component.

The granulation is formed by contacting the alkaline agent, the omeprazole, the surface active agent and the binder with a medium which may comprise any low viscosity solvent such as water, isopropyl alcohol, acetone, ethanol or the like. When fluids such as water are employed, this will usually require a weight of fluid which is about three times the weight of the dry components of the coating composition.

After the granulation is formed and dried, the granulation is tableted and the tablets are directly coated with the enteric coating agent. A color imparting agent may be added to the enteric coating agent mixture or a rapidly dissolving seal coat containing color may be coated over the enteric coating agent layer provided that the seal coat is compatible with and does not affect the dissolution of the enteric coating layer.

The rapidly dissolving seal coat may comprise Opadry™ pink which comprises approximately 91wt% hydroxypropyl methylcellulose (E-6), color and 9wt% polyethylene glycol which is applied as a 8-15% w/w solution in purified water. In addition the color may be provided as "Chromateric" which is available from Crompton & Knowles. This product contains water, CaCO_3 , TiO_2 , triethyl citrate, propylene glycol, synthetic red iron oxide, potassium sorbate, xanthan gum, sodium citrate

CA 02251430 2003-12-01

and synthetic yellow iron oxide. If desired, conventional sugar based seal coats may be used which contain FDA certified dyes.

5 DESCRIPTION OF THE PREFERRED EMBODIMENTS

EXAMPLE 1

Granulation.

A granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing micronized omeprazole, 5%w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose, 95%w/w of the total amount of L-arginine and sodium starch glycolate. The formulation for making the granulation has the following composition:

povidone, USP (Plasdone™ K30)	100.0g
sodium starch glycolate	100.0g
20 sodium lauryl sulfate, NF/USP	6.0g
microcrystalline cellulose (Avicel™ PH101)	965.6g
L-arginine, USP/ FCC	1020.0g
omeprazole, USP (micronized) ¹	340.0g
purified water, USP	1100.0g
25 ¹ 95% of the particles exhibit a particle size of less than 15 microns	

Tabletting.

The granulation is tabletting into tablets containing 20mg of omeprazole by first mixing the omeprazole granules with glyceryl monostearate:

omeprazole granules	118.0g
glyceryl monostearate (FASTMAN™ 600P)	6.0g

Tabletting tools: 0.2812"

35 target weight : 124mg/tab
target hardness : 7Kp
LOD of granules : less than 3%

CA 02251430 2003-12-01

Enteric coating.

An enteric coating was applied to prepare enteric coated tablets as follows:

5	omeprazole tablets (prepared above)	124.0g
	hydroxypropyl methylcellulose phthalate 55	14.7g
10	talc	4.2g
	acetyl tributyl citrate	2.9g
15	acetone	148.0g
	isopropyl alcohol	148.0g

The solid coating materials were dissolved in the acetone and isopropyl alcohol and this solution was coated onto the omeprazole tablets using a perforated pan.

Seal coat:

A seal coat was applied to the enteric coated tablets as follows:

	Enteric coated tablet	146.0g
	Opadry™ TT pink	4.5g
30	Water	450.0g

The seal coat was applied onto the enteric coated omeprazole tablets using a perforated pan coater.

35

EXAMPLE 2**Granulation.**

A granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing micronized omeprazole, 5.00%w/w of the total amount of L arginine, polyvinyl pyrrolidone, polysorbate 80 and purified water which is sprayed onto

7

CA 02251430 2003-12-01

a mixture of microcrystalline cellulose and 95.0%w/w of the total amount of L-arginine. The formulation for making the granulation has the following composition:

	mg/tablet
5 povidone, USP (Plasdone™ K30)	5.88
polysorbate 80 (Tween™ 80)	0.58
L-arginine, USP/FCC	60.0
omeprazole, USP (micronized) ²	20.0
microcrystalline cellulose (Avicel™ PH102)	25.54
10 purified water, USP	n/a

² 95% of the particles exhibit a particle size of less than 10 microns

Tabletting.

The granulation is tableted into tablets containing 20mg of omeprazole by first mixing the omeprazole granules with crospovidone XL, then with glyceryl monostearate:

omeprazole granules	112.0mg
glyceryl monostearate (EASTMAN™ 600P)	6.8mg
20 crospovidone XL	16.2mg

Tabletting tools: 0.2812"

target weight : 135mg/Lab

target hardness : 7Kp

25 LOD of granules : less than 3%

Enteric coating.

An enteric coating was applied to prepare enteric coated tablets as follows:

30 omeprazole tablets (prepared above)	135.0mg
Eudragit™ L30D-55	14.0mg
35 color (Chromateric)	7.0mg
1M NaOH (pH adjuster to pH 5.0)qs	na
40 Purified water qs	na

CA 02251430 2003-12-01

The solid coating materials were dispersed in the water and this mixture was coated onto the omeprazole tablets using a perforated pan.

5

EXAMPLE 3

Granulation.

A granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing micronized omeprazole, 5.0%w/w of the total amount of L-arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose and 95.0%w/w of the total amount of L-arginine. The formulation for making the granulation has the following composition:

	mg/tablet
povidone, USP (Plasdone™ K30)	5.0
sodium lauryl sulfate	0.3
L-arginine, USP/RCC	60.0
20 omeprazole, USP (micronized) ³	10.0
microcrystalline cellulose (Avicel™ PH102)	24.7
purified water, USP	n/a

³ 95% of the particles exhibit a particle size of less than 15 microns

25 Tableting.

The granulation is tableted into tablets containing 10mg of omeprazole by first mixing the omeprazole granules with sodium starch glycolate and then with glyceryl monostearate:

30 omeprazole granules	100.0mg
glyceryl monostearate (EASTMAN™ 600P)	5.0mg
sodium starch glycolate	5.0mg

Tabletting tools: 0.2812"

35 target weight : 110mg/tab

target hardness : 7Kp

LOD of granules : less than 3%

CA 02251430 2003-12-01

Enteric coating.

The tablets were coated with the same enteric coating that was applied to the tablets in Example 2.

5

EXAMPLE 4

Granulation.

A granulation containing omeprazole is formed in fluid bed coater using a top spray granulation forming suspension containing micronized omeprazole, 5.0%w/w of the total amount of L arginine, polyvinyl pyrrolidone, sodium lauryl sulfate and purified water which is sprayed onto a mixture of microcrystalline cellulose, croscopovidone XL and 95.0%w/w of the total amount of L-arginine. The formulation for making the granulation has the following composition:

	mg/tablet
povidone, USP (Plasdone [®] K30)	5.88
poly sorbate 80	0.60
L-arginine, USP/ECC	60.0
20 omeprazole, USP (micronized)*	20.0
croscopovidone XL	5.88
microcrystalline cellulose	25.54
purified water, USP	n/a
* 98% of the particles exhibit a particle size of less than 15 microns	

25

Tabletting.

The granulation is tabletting into tablets containing 20mg of omeprazole by first mixing the omeprazole granules with glyceryl monostearate:

30 omeprazole granules	117.9mg
glyceryl monostearate (EASIMAN [®] 600P)	6.1mg

Tabletting tools: 0.2812"

target weight : 124mg/tab

35 target hardness : 7Kp

LOD of granules : less than 3%

CA 02251430 2003-12-01

Enteric coating.

The tablets were coated with the same enteric coating that was applied to the tablets in Example 1.

5

EXAMPLE 5

The granulation of Example 1 was prepared and tableted into tablets containing 20.0mg of omeprazole. These tablets were coated as follows:

10

Enteric coating.

An enteric coating was applied to prepare enteric coated tablets as follows:

15

omeprazole tablets (prepared above)	126.00mg
--	----------

Eudragit [™] L30D-55	17.00mg
-------------------------------	---------

20

1M NaOH (pH adjuster to pH 5.0)qs	na
-----------------------------------	----

acetyl tributyl citrate	1.70mg
-------------------------	--------

talc	3.80mg
------	--------

25

polyorbate 80	1.50mg
---------------	--------

Purified water qs	na
-------------------	----

30

The coating polymer was diluted with water and the other coating materials were added. This mixture was coated onto the omeprazole tablets using a perforated pan. A seal coat was applied using the procedure of Example 1.

35

While certain preferred and alternative embodiments of the invention have been set forth for purposes of disclosing the invention, modifications to the disclosed embodiments may occur to those who are skilled in the art. Accordingly, the appended claims are intended to cover all embodiments of the invention and modifications thereof which do not depart from the spirit and scope of the invention.

40

CA 02251430 2004 03 10

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A stable pharmaceutical dosage formulation for oral administration consisting essentially of:

(a) a tableted core consisting essentially of 5 to 70 weight percent based on the total weight of the core of omeprazole, 0.1 to 5 weight percent based on the total weight of the core of a surface active agent, 25 to 50 weight percent based on the total weight of the core of a filler, 0.1 to 10 weight percent based on the total weight of the core of a binder and 20 to 60 weight percent based on the total weight of the core of a pharmaceutically acceptable alkaline agent, wherein the alkaline agent is selected from the group consisting of lysine and arginine; and

(b) a coating layer surrounding the core that consists of an enteric coating agent, 10 to 50 weight percent based on the total weight of the coating layer of an inert processing aid and 0 to 40 weight percent based on the total weight of the coating layer of a plasticizer wherein the coating layer is applied directly to the omeprazole containing core without a separating layer between the omeprazole containing core and coating layer.

2. A pharmaceutical composition of omeprazole as defined in claim 1, wherein the alkaline agent is arginine.

3. A pharmaceutical composition of omeprazole as defined in claim 1, wherein the enteric coating agent is selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, polyvinyl acetate phthalate, carboxymethylcellulose, and co-polymerized methacrylic acid/methacrylic acid methyl esters.

4. A pharmaceutical composition of omeprazole as defined in claim 1 wherein the surface active agent is a sodium lauryl sulfate.

CA 02251430 2003-12-01

5. A method for preparing a stable oral pharmaceutical dosage formulation which consists essentially of:

(a) forming a tablet core consisting essentially of 5 to 70 weight percent based on the total weight of the core of omeprazole, 0.1 to 10 weight percent based on the total weight of the core of a binder, 25 to 50 weight percent based on the total weight of the core of a filler, 0.1 to 5 weight percent based on the total weight percent of the core of a surface active agent and 20-60 weight percent based on the total weight of the core of an alkaline agent wherein the alkaline agent is selected from the group consisting of lysine and arginine; and

(b) applying a coating layer to the tablet core that surrounds the tablet core and consists of an enteric coating agent, 10 to 50 weight percent based on the total weight of the coating layer of an inert processing aid and 0 to 40 weight percent based on the total weight of the coating layer of a plasticizer wherein the coating layer is applied directly to the omeprazole containing tablet core without a separating layer between the omeprazole containing tablet core and coating layer.

6. The dosage formulation as defined in claim 1 wherein the core consists essentially of 10 to 30 weight percent based upon the total weight of the core of omeprazole; 0.20 to 2.0 weight percent based upon the total weight of the core of the surface active agent; 0.25 to 7.5 weight percent based upon the total weight of the core of the binder; 20 to 40 weight percent based upon the total weight of the core of the filler and 30-55 weight percent based upon the total weight of the core of the alkaline agent.

7. The dosage formulation as defined in claim 1 wherein the coating layer consists of 20 to 40 weight percent based upon the total weight of the coating layer of the inert processing aid and 10 to 20 weight percent based upon the

CA 02251430 2003-12-01

total weight of the coating layer of the plasticizer.

8. The method as defined in claim 5 wherein the core consists essentially of 10 to 30 weight percent based upon the total weight of the core of omeprazole; 0.20 to 2.0 weight percent based upon the total weight of the core of the surface active agent; 0.25 to 7.5 weight percent based upon the total weight of the core of the binder; 20 to 40 weight percent based upon the total weight of the core of the filler and 30 to 55 weight percent based upon the total weight of the core of the alkaline agent.

9. The method as defined in claim 5 wherein the coating layer consists of 20 to 40 weight percent based upon the total weight of the coating layer of the inert processing aid and 10 to 20 weight percent based upon the total weight of the coating layer of the plasticizer.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.